Skip to main content

Attend a Webinar About Upcoming Medical Injectables Program Changes

Effective January 1, 2018, Horizon BCBSNJ will change the way it considers and approves claims for certain sodium hyaluronate injections.

As previously announced, for services provided on and after January 1, 2018, Magellan Rx Management will conduct Medical Necessity and Appropriateness Reviews (MNARs) of the following sodium hyaluronate injections administered in an outpatient facility or a physician’s office1 as part of our Medical Injectables Program (MIP):

  • Hyalgan
  • Supartz FX
  • Gel-Syn
  • GenVisc 850
  • Hymovis
  • Gel-One

Join us for a webinar to learn more

To make sure you are ready for these changes, we encourage you to participate in an upcoming webinar presented by Magellan Rx Management.

In this 60-minute webinar, we will review MIP policies and procedures, the Magellan Rx Management website (including how to initiate an MNAR using Magellan Rx Management’s easy-to-use online tools), and how to check the status of a prior approval request. There will also be time dedicated for you to get answers to questions you may have.

Webinars will be presented at 8 a.m. and 12 p.m., Eastern Time, on the following dates:

  • Thursday, December 14, 2017
  • Monday, December 18, 2017

Register for the webinar

To register for a webinar, please email the following information to

  • Webinar date/time
  • Physician name and/or name of group or hospital
  • Tax Identification Number
  • Service site address
  • Email and phone contact information
  • Number of participants (please indicate if attendees are clinical and/or administrative)

Once registered, you will receive an email confirmation with instructions on how to access the webinar.

If you have questions, please contact your Network Specialist.

1 MNAR is not required for injectable medications that are administered during an inpatient stay or in an Emergency Room setting.

Published on: December 8, 2017, 12:19 p.m. ET
Last updated on: December 8, 2017, 12:21 p.m. ET